Products

Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. Daiichi Sankyo, Inc. medicines approved in the U.S. are outlined below and include therapies for metastatic breast and gastric cancer, tenosynovial giant cell tumor, metastatic melanoma, hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, and IV iron therapy.

The Products listed below, which are currently FDA approved in the U.S., are the result.

Click to view Daiichi Sankyo Products available in other countries: